Neurodegenerative Disease Management

Deutetrabenazine in the treatment of tardive dyskinesia.

Efficacy and safety of extended-release amantadine in levodopa-induced dyskinesias: a meta-analysis.

Update on current and emerging therapies for dystonia.

A physical therapy decision-making tool for stratifying persons with Parkinson disease into community exercise classes.

Abdominal functional electrical stimulation for bowel management in multiple sclerosis.

Outcome measures for chronic inflammatory demyelinating polyneuropathy in research: relevance and applicability to clinical practice.

Impact on interpersonal relationships among patients with multiple sclerosis and their partners

Diagnostic evaluation and monitoring of patients with posterior cortical atrophy.

Newest evidence for tetrahydrocannabinol:cannabidiol oromucosal spray from randomized clinical trials.

Amyloidosis: diagnosis and new therapies for a misunderstood and misdiagnosed disease.

Current management of Duchenne muscular dystrophy in the Middle East: expert report

Tetrahydrocannabinol: cannabidiol oromucosal spray for treating symptoms of multiple sclerosis spasticity: newest evidence.

Personality and the risk factors for developing behavioral and psychological symptoms of dementia: a narrative review.

Self-efficacy and walking performance across the lifespan among adults with multiple sclerosis.

Newest evidence for tetrahydrocannabinol:cannabidiol oromucosal spray from postapproval pragmatic studies.

Person-centered risk assessment framework: assessing and managing risk in older adults living with dementia.

Diagnosis and management of secondary-progressive multiple sclerosis: time for change.

Valbenazine in the treatment of tardive dyskinesia.